Welcome to a new work week, the final couple of days of July. Here is what I’m reading this morning:
- The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs (Benzinga)
- Would AbbVie’s top execs really pull the trigger on a $30B M&A deal? Why, yes, actually (Endpoints)
- 7 medtech stories we missed this week: July 27, 2018 (Mass Device)
- What is the hardest thing about medtech IoT? (Medical Design & Outsourcing)
Happy Friday! Here is what I am reading as we head into the weekend:
- Talk about hitting on a lot of points, super insightful article – Regeneron’s Billionaire Founder Battles The Drug Pricing System (Forbes).
- Bio Roundup: An Alzheimer’s Head-Scratcher, OUTBio, GSK & Gilead Shakeups (Xconomy)
- When healthcare devices go over the counter. An important trend contributing to the consumerization of healthcare is the transformation of select prescription categories to over-the-counter (Med City News)
- Six big things: Funding for females and cash pouring into China shape the week in VC (Pitchbook)
Yesterday was dominated by Biogen’s news on their Alzheimer drug, but there was other news including Sarepta getting slapped with a clincial hold, Gilead CEO stepping down and, although not Life Science related, Facebook getting crushed after their earnings. Here is what I’m reading:
- Yesterday afternoon Eisai & Biogen Revealed Promising Alzheimer’s Data But Questions Linger (Xconomy)
- How Often Do Urgent Care Clinics Offer Antibiotics When They Shouldn’t? The answer it seems is too often. I wonder why antibiotics are becoming less and less effective. (Forbes)
- These 10 startups made the cut for XLerateHealth’s sixth cohort (MedCity News). Ten Startups Selected for Inaugural Comcast NBCUniversal LIFT Labs Accelerator, Powered by Techstars (Venture Beat)
- Help wanted: New CEO to run Gilead as John Milligan steps down (EndPoints)
Check out my podcast, Life Sciences Rush Hour – Investing, News, Risk Management and any other topic impacting the space, on Apple Podcasts!
Here is what I am reading this morning:
- Glaxo’s New Research Chief Loves Big Pharma. Now He Has To Fix It (Forbes) – Highly recommended read!
- 23andMe is raising up to $300M on top of what they have already raised, valuing them at $2.5B (PitchBook).
- Venture capital firms invested more than $738 million in Medtech during the second quarter of 2018, $1 million less than the first quarter (Medical Design & Outsourcing)
- Today is the big day – Biogen’s Spinraza zooms through blockbusterland, but analysts are fixated on Alzheimer’s data (FiercePharma)
Good morning, this is what I’m reading on this hot and humid Tuesday morning:
- For Scientists Racing to Cure Alzheimer’s, the Patient Recruitment Math Is Getting Ugly (NY Times)
- Anthem In Telehealth Deal With Samsung And American Well (Forbes)
- An Enormous Study of the Genes Related to Staying in School. Researchers have found 1,271 gene variants associated with years of formal education. That’s important, but not for the obvious reasons (The Atlantic).
- FDA releases ‘Biosimilars Action Plan,’ aiming to accelerate innovation. Agency will create new review tools and other resources to encourage development of biosimilars (MedCity News)
It’s a new week and this is what I’m reading to get going:
- While Tech Waffles On Going Public, Biotech IPOs Boom (Crunchbase)
- Smart Bandage Can Dispense Drugs, While Keeping An Eye On Your Wound (FORBES)
- Tendyne investors sue Abbott over $50m milestone (MassDevice). In case you missed, my thoughts on how a company can protect themselves financially from missed or delayed milestones (MattCorc).
- Why the Theranos saga and Holmes’ trial is good for innovation (MedCity News)
Happy Friday! Here is what I am reading as we wrap up the week:
- Drug lobby aims to shake up how medicines are paid for (BioPharma Dive)
- A survey of 101 healthcare workers in IT and business/clinical positions asked respondents to rate their level of concern about insider cybersecurity threats, with 1 being not at all concerned and 10 being extremely concerned. The mean score was 8.2 (MedCity News)
- Stanford researchers are developing a bioprinter that, when paired with an advanced bacteria scanner, could speed up screening for bacterial infections (Medical Design & Outsourcing).
- FDA To Consider Drug Importation In Battle Against High Drug Prices (Forbes)